Hangzhou Youshan Biomedical

Hangzhou Youshan Biomedical is a clinical-stage biotechnology company headquartered in Hangzhou, China, dedicated to the innovation of next-generation immune cell therapies. The company primarily focuses on developing off-the-shelf universal CAR-T (UCAR-T) therapies to address unmet needs in oncology and autoimmune diseases. By utilizing proprietary gene-editing platforms, Youshan aims to produce standardized, high-quality cell products that are more accessible and cost-effective than traditional autologous treatments. Their lead candidate, YS-001, is a universal CAR-T targeting CD19, currently undergoing clinical evaluation for B-cell malignancies. The company is backed by prominent life science investors, including Qiming Venture Partners and Lilly Asia Ventures.